Shield plans £110m London IPO to fund Ferinject challenger
This article was originally published in Scrip
Executive Summary
Shield Therapeutics, which is awaiting European marketing review for its novel oral iron replacement drug Feraccru (ST10, ferric maltol), plans to raise up to £110m an initial public offering (IPO) on the London Stock Exchange. The money will fund the company "through to self-sufficiency," CEO Carl Strerrit told Scrip.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.